Funded by a $230,979 grant, an Ohio University study tests metformin to prevent Clostridioides difficile in heart patients.

Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted ...

High-dose cohort confirms the favorable safety profile and the dose-dependent immune response against Clostridioides ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile - commonly known as C. diff - are a serious and persistent problem for patients and ...

Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx previously announced that it had received positive regulatory guidance from the ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...

There are trillions of bacteria that live in your colon. Most of them are harmless and many are actually helpful, supporting digestion and keeping your immune system strong. C. diff is one type of ...

There are about half a million C. diff infections every year in the United States. About 30,000 people die from them annually. But if you’ve had C. diff, you’re more likely to get it again. About 1 in ...

STATEN ISLAND, N.Y., March 9, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of ...

High-dose cohort confirms the favorable safety profile and the dose-dependent immune response against Clostridioides difficile bacteria and spores Allschwil, Switzerland - June 1, 2026Idorsia Ltd (SIX ...